| Budget Amount *help |
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
We evaluated the expression and clinical significance of cancer stem-like cells (CSLC) markers in high-grade neuroendocrine carcinoma (HGNEC) of the lung, comprising small cell lung carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC) in order to develop new treatment strategy. The expression of putative CSLC markers were examined immunohistochemically by using resected tumor specimens. HGNEC of the lung had various range of positive expression of CSLC markers. Among explored CSLC markers, ALDH1 expression was related to patient outcomes. ALDH1-positive HGNEC had significantly poorer survival than those with ALDH1- negative HGNEC. Multivariate analysis also revealed positive ALDH1 expression as an independent unfavorable prognostic factors. ALDH1-positive tumor cells were frequently observed even in micro lymph node metastases. These induced that targeting for ALDH1-positive tumor cells might be a future treatment strategy in HGNEC of the lung.
|
